Delta Airlines Manila Office in Philippines – Location, Contact Details, and Passenger Services

Equitable access to safe and effective vaccines is critical to ending the COVID-19 pandemic, so it is hugely encouraging to see so many vaccines proving and going into development. WHO is working tirelessly with partners to develop, manufacture and deploy safe and effective vaccines. Safe and effective vaccines are a game-changing tool: but for the foreseeable future we must continue wearing masks, cleaning our hands, ensuring good ventilation indoors, physically distancing and avoiding crowds. Being vaccinated does not mean that we can throw caution to the wind and put ourselves and others at risk, particularly because research is still ongoing into how much vaccines protect not only against disease but also against infection and transmission. See WHO’s landscape of COVID-19 vaccine candidates for the latest information on vaccines in clinical and pre-clinical development, generally updated twice a week. WHO’s COVID-19 dashboard, updated daily, also features the number of vaccine doses administered globally, with more detail provided on the dedicated COVID-19 vaccination dashboard. At a regional level, there is an AFRO COVID-19 vaccines dashboard and a PAHO COVID-19 vaccines deliveries dashboard. But it’s not vaccines that will stop the pandemic, it’s vaccination. We must ensure fair and equitable access to vaccines, and ensure every country receives them and can roll them out to protect their people, starting with the most vulnerable. You can follow the status of COVID-19 Vaccines within WHO EUL/PQ evaluation process here. Learn more Public advice Country readiness and delivery Guidance COVAX ACT-Accelerator SAGE Recommendations Emergency use listing COVID-19 Vaccine equity Public Advice "Vaccines Explained" series Science in 5: COVID-19 questions answered Public advice on getting vaccinated Vaccines explained series Science in 5 Getting vaccinated Q&As Coronavirus disease (COVID-19): Vaccines Coronavirus disease (COVID-19): Vaccines safety Coronavirus disease (COVID-19): Vaccine access and allocation Coronavirus disease (COVID-19): Vaccine research and development Coronavirus disease (COVID-19): Use of Emergency Use Listing procedure for vaccines against COVID-19 Vaccines and immunization: What is vaccination? Vaccines and immunization: Vaccine safety 15 February 2022 Questions and Answers: COVID-19 vaccines and pregnancy COVAX and vaccine introduction COVAX COVAX aims to accelerate the development and manufacturing of COVID-19 vaccines, and guarantee fair and equitable access for every country. COVAX is co-led by the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi and WHO, with UNICEF as a key delivery partner and PAHO as the procurement agent in the Americas. Country readiness and delivery WHO has worked with UNICEF, Gavi and partners to develop resources, such as guidance, trainings, tools and advocacy materials to help governments, health workers and partners to launch, refine, and optimise uptake of their COVID-19 vaccination programmes. COVAX No fault compensation program The COVAX No-Fault Compensation Program for Advance Market Commitment (AMC) Eligible Economies is the world’s first and only international vaccine injury compensation mechanism. The Program helps COVAX deliver safe and effective COVID-19 vaccines to the high-risk and vulnerable populations in 92 low- and middle-income countries and economies. Regulation and policy Emergency Use Listing (EUL) WHO's EUL procedure is a risk-based procedure for assessing and listing unlicensed vaccines, therapeutics and in vitro diagnostics with the ultimate aim of expediting the availability of these products to people affected by a public health emergency. Strategic Advisory Group of Experts (SAGE) on Immunization SAGE advises WHO on overall global policies and strategies, ranging from vaccines and technology, research and development, to delivery of immunization and its linkages with other health interventions. Draft landscape of COVID-19 vaccine candidates The draft landscape of COVID-19 vaccine candidates contains information on vaccine candidates collected through public information (e.g. clinical trial registries) and information that were directly provided by vaccine developers to WHO. The landscape is generally updated twice a week, based on the latest information, including those we receive from scientists and research COVID-19 vaccines: product-by-product information 21 January 2022 The Pfizer BioNTech (BNT162b2) COVID-19 vaccine: What you need to know 3 November 2021 The Bharat Biotech BBV152 COVAXIN vaccine against COVID-19: What you need to know 2 September 2021 The Sinovac-CoronaVac COVID-19 vaccine: What you need to know 7 May 2021 The Sinopharm COVID-19 vaccine: What you need to know 23 February 2022 The Moderna COVID-19 (mRNA-1273) vaccine: what you need to know 2 September 2021 The Oxford/AstraZeneca (ChAdOx1-S [recombinant] vaccine) COVID-19 vaccine: what you need to know 2 September 2021 The Janssen Ad26.COV2.S COVID-19 vaccine: What you need to know 21 December 2021 The Novavax vaccine against COVID-19: What you need to know Latest vaccine news All → 8 March 2022 Statement Interim Statement on COVID-19 vaccines in the context of the circulation of the Omicron SARS-CoV-2 Variant from the WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC), 08 March 2022 7 March 2022 Statement Eighth Meeting of the Multilateral Leaders Task Force on COVID-19, 1 March 2022: "Third Consultation with the CEOs of leading vaccine manufacturers" 23 February 2022 News release Moving forward on goal to boost local pharmaceutical production, WHO establishes global biomanufacturing training hub in Republic of Korea 9 February 2022 News release ACT-Accelerator calls for fair share-based financing of US$ 23 billion to end pandemic as global emergency in 2022 Multimedia